GSK3039294

DRUG2 trials

Sponsors

GlaxoSmithKline

Conditions

Amyloidosis

Phase 1

A Safety Study of GSK3039294 in Healthy Volunteers and Patients With Systemic Amyloidosis

TerminatedNCT02603172

GlaxoSmithKlineAmyloidosis

Start: 2016-05-12End: 2017-05-10Updated: 2019-09-23

Pro-arrhythmic Potential of GSK3039294 in Healthy Subjects

WithdrawnNCT03567499

GlaxoSmithKlineAmyloidosis

Start: 2018-07-12End: 2019-05-03Updated: 2018-10-09